ADELAIDE, Australia, Jan. 09, 2026 (GLOBE NEWSWIRE) — Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced today that its executive team will attend Biotech Showcase 2026 in San Francisco, January 12-14, to meet with innovative biotech sponsors and highlight the company's newly launched […]
(NASDAQ:IMCR), Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications – TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026
PRESS RELEASE Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes First conceptual model demonstrating the impact of BK polyomavirus on the health-related quality of life of kidney transplant recipients Study conducted in partnership with Northwestern University and presented at the World Transplant Congress in August 2025 Schlieren /
CoinUp Announces Release Of Its 2025 Report Card: From Growth to Compliance, the Rise of Second-Tier Exchanges GlobeNewswire January 09, 2026 SINGAPORE, Jan. 09, 2026 (GLOBE NEWSWIRE) — CoinUp announced the release of its 2025 Report Card, detailing a year of accelerated user growth, strengthened regulatory compliance, disciplined product execution, and expanding global presence. As
— The second tranche of the share buyback is expected to be executed by May 8, 2026 — The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally planned Fresenius Medical Care (FME), the world’s leading provider of products
Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for demyelinating diseases, today announced that it closed its Series A Extension Round of CAD$10 million from current investors CTI Life Sciences, Investissement Québec and adMare BioInnovations. The financing follows the successful completion of a Phase I clinical trial in healthy subjects
Retailer finalizes sale to iHerb The Kroger Co. (NYSE: KR) today announced the sale of its subsidiary, Vitacost.com, Inc., an eCommerce retailer of health and wellness products, to iHerb. The transaction closed on January 8. “As we shared earlier this fiscal year, we are reviewing all non-core assets to determine their ongoing contribution and role
BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025– ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with Unaudited Global Revenues of Approximately $433.8 Million– Full-Year 2026 Global ARIKAYCE Revenues Expected to be Between $450 Million
Nona Biosciences (“Nona”), a global biotechnology company advancing biologics discovery through innovative technology platforms, today announced that it has entered into a multi-target antibody discovery collaboration with Link Cell Therapies. This collaboration will leverage Nona’s proprietary fully human HCAb Harbour Mice® platform and its innovative direct CAR-function-based HCAb library screening platform, NonaCarFx(TM), to generate novel
Quarterhill Inc. (“Quarterhill” or the “Company”) (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System (“ITS”) industry, today announced that its management team will present virtually at the 28th Annual Needham Growth Conference, highlighting continued execution across its operational transformation and expanding global ITS footprint. Quarterhill CEO